CPRX News and Press, Catalyst Pharmaceuticals Inc. From 03/24/21

Supernus Pharmaceuticals (NASDAQ: SUPN) , Corcept Therapeutics (NASDAQ: CORT) , and Catalyst Pharmaceuticals (NASDAQ: CPRX) don't have much in common. But it does so happen that they're all in the healthcare space, trade for less than $26 per share, and have the pote...

Should You Be Watching These 4 Penny Stocks This Week? March has been an interesting month for penny stocks, to say the least. While most days have been bullish for penny stock investors, underlying factors have pushed some days to be bearish. In the market right now, there are several ...

Some Of The Best Penny Stocks To Watch Early This Week This week has started stronger than the last & we have plenty of trending penny stocks to watch as a result. Last week the markets sold off, with tech continuing its move lower. What’s more, over the weekend, new virus da...

Catalyst Pharmaceuticals (CPRX) has authorized the repurchase of up to $40M worth of its common shares.The company expects to use existing cash on hand for the repurchases.Catalyst is focuses on developing therapies for rare chronic neuromuscular and neurological diseases.Catalyst shares...

CORAL GABLES, Fla., March 22, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurologic...

Catalyst Pharmaceuticals reported its Q4 results highlighted by record revenues from its Firdapse drug, as the only FDA-approved treatment of LEMS disease. The company expects momentum to continue with the end of the pandemic allowing for new patients to be diagnosed and receive a pre...

Start Time: 08:30 End Time: 09:18 Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2020 Earnings Conference Call March 16, 2021, 08:30 AM ET Company Participants Patrick McEnany - Co-Founder, Chairman and CEO Alicia Grande - VP, CFO and Treasurer Steven Miller - COO and Chief Scientific Officer Jeff ...

Catalyst Pharmaceuticals (CPRX): Q4 GAAP EPS of $0.11 beats by $0.02.Revenue of $31.01M (+3.0% Y/Y) beats by $0.95M.Cash and investments of $140.3M.Shares +1.5% AH.Press Release For further details see: Catalyst Pharmaceuticals EPS beats by $0.02, beats on revenue

- Firdapse ® Q4-20 Net Revenues of $31.0 Million, FY-20 Net Revenues of $119.1 Million - GAAP Net Income of $75.0 Million for Fiscal Year 2020 - $140.3 Million in Cash and Investments and No Funded Debt - Company to Host Quarterly Conference Call at 8:30 a...

CORAL GABLES, Fla., March 04, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurologi...